Hedge fund Davidson Kempner has raised its stake in takeover target Qiagen to 7.3% from 5.1% previously, having rejected a sweetened offer for the German group from U.S. laboratory equipment supplier Thermo Fisher.
Thermo Fisher in mid-July raised its bid for Qiagen by 900 million euros ($1 billion) to 11.3 billion euros but failed to win over Davidson Kempner, a key investor in the German company.
The hedge fund on Friday said Thermo Fisher was free to relaunch the offer immediately with Qiagen’s approval if it fails to reach the shareholder acceptance threshold on Aug. 10.
It added that Qiagen’s non-executive Chairman Hakan Bjorklund and the board may not be clear about this.
“Following our call with Dr. Bjoerklund on 30 July 2020, we are deeply concerned that there is a misunderstanding of the German tender rules amongst the board and possibly amongst shareholders, particularly with regards to the 12-month blocking period applicable after an offer fails,” the hedge fund said in an open letter to Qiagen directors and top executives.
As part of the sweetened offer, Thermo Fisher reduced the minimum acceptance threshold to 66.67% of the target’s share capital from 75% and extended the deadline to vote on the deal by two weeks until Aug. 10.
Qiagen was not immediately available to comment.
Source: Reuters.com